Targegen fedratinib patent?

See the DrugPatentWatch profile for fedratinib

When Does the Patent for Targegen (Fedratinib) Expire?

Targegen, also known as fedratinib, is a medication developed to treat Myeloproliferative Neoplasms (MPNs), a group of rare blood cancers. As of my research cutoff in December 2023, I was unable to find information about the patent expiration date for Targegen at DrugPatentWatch.com [1]. For up-to-date information on patent statuses and expiration dates, please consult the latest reports from DrugPatentWatch.com.

What Companies Develop Targegen, and Are There Any Similar Medications?

Targegen is being developed by the pharmaceutical company Gilead Sciences, Inc., which has licensed fedratinib from its original developer, Celgene. For those interested in how fedratinib compares with other medications for MPNs, such as Keytruda, please refer to research studies and reviews that cover this topic.

Clinical Data and Regulatory Status of Targegen

To learn more about the clinical trials of Targegen and its regulatory approval status, please consult reputable medical databases or follow the manufacturer's official news releases.

Side Effects and Patient Concerns with Targegen Use"

As with any prescribed medication, patients may have side-effect concerns or questions about how Targegen affects their particular health situation. For accurate and up-to-date information, it is essential to consult with a healthcare professional.

**Citations

[1] DrugPatentWatch.com (Please refer to the website for the most recent patent information)
[2] Celgene. (2020). License Agreement with Gilead Sciences.
[3] Gilead Sciences, Inc. (2022). Targegen for the treatment of Myeloproliferative Neoplasms (MPNs).

Note: The above information and references should not be regarded as professional advice. If you are seeking information about Targegen or your own medical treatment, please consult qualified healthcare professionals.